Literature DB >> 21519898

Inflammation and benign prostatic hyperplasia: clinical implications.

Bilal Chughtai1, Richard Lee, Alexis Te, Steven Kaplan.   

Abstract

Prostatic inflammation may be a large contributor to hyperplastic changes in the prostate. There have been several studies looking at the varieties of growth factors and cytokines that are involved in both the inflammatory process and in the epithelial/stromal prostatic cells interactions. We reviewed the recent international literature using a PubMed search to analyze new findings supporting a role for inflammation in benign prostatic hyperplasia (BPH) progression. This article reviews the factors that lead to both intrinsic and extrinsic causes of prostatic inflammation. There are several exciting studies supporting that inflammation can promote chronic prostatic diseases, such as BPH.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21519898     DOI: 10.1007/s11934-011-0191-3

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  18 in total

Review 1.  Chronic prostatitis-an infectious disease?

Authors:  K G Naber; W Weidner
Journal:  J Antimicrob Chemother       Date:  2000-08       Impact factor: 5.790

Review 2.  BPH: epidemiology and comorbidities.

Authors:  Kevin T McVary
Journal:  Am J Manag Care       Date:  2006-04       Impact factor: 2.229

3.  Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels.

Authors:  R B Nadler; P A Humphrey; D S Smith; W J Catalona; T L Ratliff
Journal:  J Urol       Date:  1995-08       Impact factor: 7.450

4.  Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study.

Authors:  Siavash Falahatkar; Gholamreza Mokhtari; Farshid Pourreza; Seyed Alaeddin Asgari; Alireza Noshad Kamran
Journal:  Urology       Date:  2008-08-09       Impact factor: 2.649

5.  Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate.

Authors:  Georg E Steiner; Martin E Newman; Doris Paikl; Ursula Stix; Nima Memaran-Dagda; Chung Lee; Michael J Marberger
Journal:  Prostate       Date:  2003-08-01       Impact factor: 4.104

6.  BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay.

Authors:  R Vela Navarrete; J V Garcia Cardoso; A Barat; F Manzarbeitia; A López Farré
Journal:  Eur Urol       Date:  2003-11       Impact factor: 20.096

7.  Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium.

Authors:  Wanzhong Wang; Anders Bergh; Jan-Erik Damber
Journal:  Prostate       Date:  2004-09-15       Impact factor: 4.104

8.  The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways.

Authors:  Giuseppe Penna; Benedetta Fibbi; Susana Amuchastegui; Elisa Corsiero; Gilles Laverny; Enrico Silvestrini; Aravinda Chavalmane; Annamaria Morelli; Erica Sarchielli; Gabriella Barbara Vannelli; Mauro Gacci; Enrico Colli; Mario Maggi; Luciano Adorini
Journal:  Prostate       Date:  2009-04-01       Impact factor: 4.104

9.  Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis.

Authors:  Grégoire Robert; Aurélien Descazeaud; Nathalie Nicolaïew; Stéphane Terry; Nanor Sirab; Francis Vacherot; Pascale Maillé; Yves Allory; Alexandre de la Taille
Journal:  Prostate       Date:  2009-12-01       Impact factor: 4.104

10.  Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial.

Authors:  J Curtis Nickel; Claus G Roehrborn; Michael P O'leary; David G Bostwick; Matthew C Somerville; Roger S Rittmaster
Journal:  J Urol       Date:  2007-07-16       Impact factor: 7.450

View more
  5 in total

1.  Targeting androgen receptor to suppress macrophage-induced EMT and benign prostatic hyperplasia (BPH) development.

Authors:  Tianjing Lu; Wen-Jye Lin; Kouji Izumi; Xiaohai Wang; Defeng Xu; Lei-Ya Fang; Lei Li; Qi Jiang; Jie Jin; Chawnshang Chang
Journal:  Mol Endocrinol       Date:  2012-08-21

2.  Prostate-specific PTen deletion in mice activates inflammatory microRNA expression pathways in the epithelium early in hyperplasia development.

Authors:  D Alwyn Dart; Pinar Uysal-Onganer; W G Jiang
Journal:  Oncogenesis       Date:  2017-12-14       Impact factor: 7.485

3.  The Expression of Transforming Growth Factor Beta-1 and Interleukin-6 on Human Prostate: Prostate Hyperplasia and Prostate Cancer.

Authors:  Afdal Afdal; Eryati Darwin; Yanwirasti Yanwirasti; Rizal Hamid
Journal:  Open Access Maced J Med Sci       Date:  2019-06-30

4.  Potential Therapeutic Effects of Underground Parts of Kalanchoe gastonis-bonnieri on Benign Prostatic Hyperplasia.

Authors:  Antonio Palumbo; Livia Marques Casanova; Maria Fernanda Paresqui Corrêa; Nathalia Meireles Da Costa; Luiz Eurico Nasciutti; Sônia Soares Costa
Journal:  Evid Based Complement Alternat Med       Date:  2019-01-02       Impact factor: 2.629

5.  Serenoa repens and Urtica dioica Fixed Combination: In-Vitro Validation of a Therapy for Benign Prostatic Hyperplasia (BPH).

Authors:  Miriam Saponaro; Isabella Giacomini; Giulia Morandin; Veronica Cocetta; Eugenio Ragazzi; Genny Orso; Ilaria Carnevali; Massimiliano Berretta; Mariangela Mancini; Francesco Pagano; Monica Montopoli
Journal:  Int J Mol Sci       Date:  2020-12-02       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.